CSL Behring
A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)
- Conditions
- Hereditary Angioedemas
- First Posted Date
- 2025-06-03
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 200
- Registration Number
- NCT07001280
Effect of Food on the Oral Bioavailability of a Prolonged-release Formulation of Vamifeport in Healthy Adults
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Vamifeport (PR formulation)
- First Posted Date
- 2025-05-30
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 28
- Registration Number
- NCT06996184
- Locations
- 🇬🇧
Investigator Site 82600083, Leeds, West Yorkshire, United Kingdom
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 30
- Registration Number
- NCT06806657
- Locations
- 🇺🇸
Bernstein Clinical Research Center, LLC, Cincinnati, Ohio, United States
🇺🇸Research Solutions of Arizona, Litchfield Park, Arizona, United States
🇺🇸Donald Levy M.D., Orange, California, United States
Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
- Conditions
- Congenital Hemophilia A
- Interventions
- Biological: Recombinant single-chain factor VIII (rVIII-SingleChain)
- First Posted Date
- 2024-12-17
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 60
- Registration Number
- NCT06738485
- Locations
- 🇨🇳
North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China
🇨🇳Shanghai Jiaotong University School of Medicine, Ruijin Hospital, Shanghai, Shanghai, China
🇨🇳The second affiliated hospital of Kunming Medical University, Kunming, Yunan, China
Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy Adults
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 22
- Registration Number
- NCT06726863
- Locations
- 🇬🇧
Investigator Site 82600083, Leeds, West Yorkshire, United Kingdom
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- Conditions
- Sickle Cell Disease Vaso-occlusive Crisis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 260
- Registration Number
- NCT06699849
- Locations
- 🇺🇸
University of California Irvine, Orange, California, United States
🇺🇸The Foundation for Sickle Cell Disease, Hollywood, Florida, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery
- Conditions
- Acquired Fibrinogen Deficiency
- Interventions
- Biological: CSL511 Fibrinogen concentrate (human)Biological: Cryoprecipitate
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 90
- Registration Number
- NCT06617897
- Locations
- 🇬🇧
Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom
Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
- Conditions
- Post-COVID Postural Orthostatic Tachycardia Syndrome
- Interventions
- Biological: Placebo
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 177
- Registration Number
- NCT06524739
- Locations
- 🇺🇸
University of Alabama Hospital at Birmingham, Birmingham, Alabama, United States
🇺🇸Center for Complex Neurology, EDS & POTS, Phoenix, Arizona, United States
🇺🇸Mayo Clinic Arizona, Scottsdale, Arizona, United States
Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy
- Conditions
- Hemophilia B
- Interventions
- Biological: Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 23
- Registration Number
- NCT06399289
- Locations
- 🇨🇳
Beijing Children's Hospital, Beijing, Beijing, China
🇨🇳Union Hospital Affiliated to Fujian Medical University, Fuzhou, Fujian, China
🇨🇳Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B
- Conditions
- Hemophilia B
- Interventions
- Biological: Factor IX (FIX)Genetic: HEMGENIX
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 500
- Registration Number
- NCT06008938
- Locations
- 🇺🇸
American Thrombosis and Hemostasis Network, Rochester, New York, United States